Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer

Endometrial cancer is the most common gynaecological cancer in high-income countries, with an increasing incidence worldwide.1 Survival is highly correlated with stage, making early detection and treatment essential. Although the number of cancers diagnosed among younger women is increasing, most endometrial cancers are still detected in perimenopausal or postmenopausal patients at an early stage when they present with abnormal uterine bleeding. Clinical evaluation includes pelvic examination, imaging, and endometrial biopsy.